BridgeBio Pharma
BBIO
76.03
-2.15
-2.75%
BridgeBio Pharma
US · BBIO
#1254 by market cap
Listed 2019
76.03
-2.15
-2.75%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:01
About BridgeBio Pharma
BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Francis Patrick McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.
- Founded
- 2015
- CEO
- Dr. Neil Kumar, PhD
- Employees
- 839
- Headquarters
- Palo Alto, California, United States of America
- Fiscal year end
- 12-31
- Website
- bridgebio.com
Company profile
- Exchange
- US
- Symbol
- BBIO
- Market-cap rank
- #1254
- Listing date
- 2019-06-27
- Market cap
- 14.81B
- Float cap
- 12.39B
- Shares out
- 194.80M
- Float shares
- 163.01M
Sectors & themes
Biotechnology
Fractional Shares JP
Quote time 2026-11-20 20:01:24 · For reference only, not investment advice and not tailored to your situation.
BridgeBio Pharma discussion 0 comments